CHO-H01
Sponsors
Cho Pharma Inc.
Conditions
Follicular LymphomaNon-Hodgkin Lymphoma
Phase 1
A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma
NCT03221348
Start: 2018-03-31End: 2019-11-30Target: 24Updated: 2018-01-24
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Active, not recruitingNCT05950165
Start: 2020-01-15End: 2026-12-23Target: 37Updated: 2026-08-17